Cancer.Net Associate Editor: Melanoma/Skin Cancers
Massachusetts General Hospital Cancer Center, Boston, MA
Dr. Ryan Sullivan is board certified in Medical Oncology and an Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH). He attended Colby College for undergraduate studies and then matriculated to the University of Connecticut Medical School, graduating in 2001. He first trained in Internal Medicine at Mount Auburn Hospital in Cambridge, MA and then at Beth Israel Deaconess Medical Center (BIDMC) in Hematology/Oncology. He joined the MGH Cancer Center in 2011 and serves as a member of the Center for Melanoma and the Teermer Center for Targeted Therapy. He is an Assistant Professor at Harvard Medical School.
Dr. Sullivan is an active clinical and translational investigator whose main areas of interest are the development of novel therapeutic strategies for malignant melanoma, the translation of promising preclinical findings into early stage clinical trials, and the development of predictive biomarkers for investigational and standard treatment approaches. He is the Principal Investigator on multiple phase I clinical trials and is leading a number of biomarker studies in people with melanoma. He has authored more than 70 research articles, abstracts and reviews in the peer-reviewed literature.
Disclosures: Dr. Sullivan has served as a consultant and/or advisor to Astex Pharmaceuticals, Novartis, Biodesix, and Paometheus.
Last Updated: September 2016